Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (868)	7/22/1999 9:35:00 AM
From: Danny Hayden	Read Replies (1) \| Respond to of 942

Warner-Lambert soars in 2Q Sales of Lipitor power gains; Baxter International also on target July 22, 1999: 8:39 a.m. ET NEW YORK (CNNfn) - Warner-Lambert Co. posted a 36 percent increase in net income for the second quarter Thursday, matching Wall Street's expectations, as sales of its cholesterol lowering medication Lipitor soared worldwide. Also Thursday, medical products company Baxter International Inc. reported a 16 percent rise in second-quarter net profits. Strong sales of its blood therapy and anesthetic products, among others, fueled the gains. Warner-Lambert (WLA), which also makes consumer products including Listerine mouthwash and Sudafed cold and sinus medication, earned $447 million, or 51 cents per diluted share, on a net basis as sales rose 17 percent to $3.2 billion. In the 1998 period, net earnings totaled $329 million, or 37 cents per share. The latest results matched, to the penny, the consensus forecasts reported by First Call Corp. The Morris Plains, N.J.-based company said it is on target to reach full-year goals of 30 percent growth in earnings per share, for a total of about $1.92. For 2000, per-share earnings should rise about 20 percent, the company said. Total pharmaceutical sales rose 26 percent to $1.9 billion. Sales of Lipitor totaled $886 million, up 66 percent from $533 million in the year-ago quarter. The company said Lipitor is the most-prescribed cholesterol-lowering medication in the United States, with a 41 percent share of new prescriptions. Other drugs including the HIV protease inhibitor Viracept and the anticonvulsant Neurontin also helped power its pharmaceutical gains, Warner-Lambert said. Consumer product sales rose 8 percent to $731 million. The stock added ¼ to close at 69-13/16 Wednesday. Meanwhile, Baxter's net income totaled $207 million, or 70 cents per diluted share, up from $179 million, or 62 cents per share, in the 1998 second quarter. The results beat the First Call consensus forecast by a penny per share. The 1998 results exclude charges associated with its acquisition of Somatogen Inc., a developer of specialty oxygen therapeutics. Baxter's sales rose 9 percent to $1.79 billion. Last week, the Deerfield, Ill.-based firm announced plans to spin off its cardiovascular medicine business as a separately traded company. The unit accounts for about $1 billion worth of sales annually. Baxter (BAX) shares gained 13/16 to 66-1/8 Wednesday.

To: Bull-like who wrote (868)	9/30/1999 3:31:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

RESEARCH ALERT-Schroders details drug coverage biz.yahoo.com Excerpts: NEW YORK, Sept 30 (Reuters) - Schroders Securities on Thursday gave details on its start of coverage of five pharmaceutical companies. -- It added to its recommended list Bristol-Myers Squibb Co. (NYSE:BMY - news), Pfizer Inc. (NYSE:PFE - news) and Warner-Lambert Co. (NYSE:WLA - news) at outperform significantly. Warner-Lambert: -- Set 12-month price target of $85. -- Said it expects Warner-Lambert to grow EPS at a compounded annual pace of 20 percent from 1998 to 2003. -- Said while it is quite dependent on single growth driver, Lipitor, associated risks with the drug are low. -- Agouron acquisition and Warner's own promising pipeline to add sources of growth.